PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34481524-2	2021	OBJECTIVE: To evaluate feasibility of conducting a definitive trial and assessing the potential efficacy of tranexamic acid on ovarian reserve and intra-operative blood loss by comparing mean differences in anti-Mullerian hormone (AMH) levels following laparoscopic ovarian cystectomy between tranexamic acid and control groups.	Tranexamic Acid	108-123	anti-Mullerian hormone	Homo sapiens	231-234	
34481524-2	2021	OBJECTIVE: To evaluate feasibility of conducting a definitive trial and assessing the potential efficacy of tranexamic acid on ovarian reserve and intra-operative blood loss by comparing mean differences in anti-Mullerian hormone (AMH) levels following laparoscopic ovarian cystectomy between tranexamic acid and control groups.	Tranexamic Acid	108-123	anti-Mullerian hormone	Homo sapiens	207-229	
34481524-2	2021	OBJECTIVE: To evaluate feasibility of conducting a definitive trial and assessing the potential efficacy of tranexamic acid on ovarian reserve and intra-operative blood loss by comparing mean differences in anti-Mullerian hormone (AMH) levels following laparoscopic ovarian cystectomy between tranexamic acid and control groups.	Tranexamic Acid	293-308	anti-Mullerian hormone	Homo sapiens	207-229	
34481524-2	2021	OBJECTIVE: To evaluate feasibility of conducting a definitive trial and assessing the potential efficacy of tranexamic acid on ovarian reserve and intra-operative blood loss by comparing mean differences in anti-Mullerian hormone (AMH) levels following laparoscopic ovarian cystectomy between tranexamic acid and control groups.	Tranexamic Acid	293-308	anti-Mullerian hormone	Homo sapiens	231-234	
34481524-6	2021	The primary outcome was the feasibility of conducting a definitive trial in terms of design and procedures (such as recruitment rate, retention, safety of intravenous 1 gm of TXA, sample size verification) and assess the efficacy of TXA on the ovarian reserve and intra-operative blood loss by comparing mean difference of AMH levels between TXA and control groups at pre- and 3 months post-surgery.	Tranexamic Acid	342-345	anti-Mullerian hormone	Homo sapiens	323-326	
34481524-9	2021	The mean difference of serum AMH levels (pre- and 3 months post-surgery) between the TXA and control groups was not significantly different.	Tranexamic Acid	85-88	anti-Mullerian hormone	Homo sapiens	29-32	
35426283-1	2022	Objective: A prospective randomized controlled trial was conducted to study the effectiveness and safety of intravenous different doses tranexamic acid (TXA) in single-level unilateral minimally invasive transforaminal lumbar interbody fusion (MIS-TLIF).	Tranexamic Acid	136-151	anti-Mullerian hormone	Homo sapiens	244-247	
35426283-1	2022	Objective: A prospective randomized controlled trial was conducted to study the effectiveness and safety of intravenous different doses tranexamic acid (TXA) in single-level unilateral minimally invasive transforaminal lumbar interbody fusion (MIS-TLIF).	Tranexamic Acid	153-156	anti-Mullerian hormone	Homo sapiens	244-247	
35426283-12	2022	Conclusion: Intravenous administration of TXA in single-level unilateral MIS-TLIF is effective and safe in reducing postoperative TBL and HBL within 1 day in a dose-dependent manner.	Tranexamic Acid	42-45	anti-Mullerian hormone	Homo sapiens	73-76